Bullous pemphigoid associated with Grover disease: a specific toxicity of anti‐ <scp>PD</scp> ‐1 therapies?-Reference-Cited by-同舟云学术

Bullous pemphigoid associated with Grover disease: a specific toxicity of anti‐ PD ‐1 therapies?

Published:2022-01-24 Issue:6 Volume:61 Page:
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatology

Author:

Jendoubi Fatma¹^ORCID,Sibaud Vincent²,Meyer Nicolas²,Tournier Emilie³,Fortenfant Françoise⁴,Livideanu Cristina Bulai¹,Paul Carle¹,Konstantinou Maria‐Polina¹

Affiliation:

1. Dermatology Department CHU de Toulouse et Université Paul Sabatier Toulouse France

2. Dermatology Department Institut Universitaire du Cancer et CHU de Toulouse Toulouse France

3. Pathology Department Institut Universitaire du Cancer et CHU de Toulouse Toulouse France

4. Immunology Department CHU de Toulouse et Université Paul Sabatier Toulouse France

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.16068

Reference5 articles.

1. Dermatologic Reactions to Immune Checkpoint Inhibitors

2. Grover disease and bullous pemphigoid: a clinicopathological study of six cases

3. Generalized pruritic eruption with suprabasal acantholysis preceeding the development of bullous pemphigoid

4. Grover disease: review of subtypes with a focus on management options

5. Association between bullous pemphigoid and malignancy: A meta-analysis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of bullous pemphigoid and Grover disease induced by immune checkpoint therapy;Anais Brasileiros de Dermatologia;2024-09

2. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience;Frontiers in Medicine;2023-07-20

3. Concomitant nivolumab‐associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma;Journal of Cutaneous Pathology;2023-01-24

4. Nivolumab/omalizumab/prednisone;Reactions Weekly;2022-08-06